Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

Journal of the National Cancer Institute

Volumn 96, Issue 15, 2004, Pages 1133-1141

  Cappuzzo, Federico ^a   Magrini, Elisabetta ^a   Ceresoli, Giovanni Luca ^b   Bartolini, Stefania ^a   Rossi, Elisa ^c   Ludovini, Vienna ^d   Gregorc, Vanesa ^b   Ligorio, Claudia ^a   Cancellieri, Alesandra ^a   Damiani, Stefania ^a   Spreafico, Anna ^b   Paties, Carlo Terenzio ^b   Lombardo, Laura ^a   Calandri, Cesare ^a   Bellezza, Guido ^d   Tonato, Maurizio ^d   Crino, Lucio ^a  

^a BELLARIA HOSPITAL   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c CINECA   (Italy)

^d POLICLINICO MONTELUCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CELL PROLIFERATION; CIGARETTE SMOKING; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOLOGY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT ATTITUDE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RISK REDUCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; ANALYSIS OF VARIANCE; CANCER STAGING; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM STAGING; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 4444332925     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh217     Document Type: Article

References (49)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
3. Salomon D, Gullick W. The erbB family of receptors and their ligands: multiple targets for therapy. Signal 2001;2:4-11.
4. Ciardello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7: 2958-70.
5. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002;29(5 Suppl 14):3-9.
6. Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibition in non-small cell lung cancer. Semin Oncol 2002;29(5 Suppl 14):38-44.
7. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998;74:49-139.
8. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell 1997;88:435-7.
9. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41.
10. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318-21.
11. Hemmings BA. AKT signaling: linking membrane events to life and death decision. Science 1997;275:628-30.
12. Kulik G, Weber MJ. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol 1998;18: 6711-8.
13. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997;17:1595-606.
14. Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000;60:5451-5.
15. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61:3986-97.
16. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A 1996;93:3636-41.
17. Vasko V, Saji M, Hardy E, Kruhlak M, Larin A, Savchenko V, et al. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 2004;41:161-70.
18. Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000;19:2324-30.
19. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A 1992;89:9267-71.
20. Lee SH, Kim HS, Park WS, Kim SY, Lee KY, Kim SH, et al. Non-small cell lung cancer frequently express phosphorylated Akt; an immunohistochemical study. APMIS 2002;110:587-92.
21. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995;267:1782-8.
22. Levitt ML, Koty PP. Tyrosine kinase inhibitors in preclinical development. Invest New Drugs 1989;7:213-26.
23. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, et al. Antitumour effect and potentiation of cytotoxic drug activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6: 2053-63.
24. Kris MG, Herbst R, Rischin D, LoRusso P, Baselga J, Hammond L, et al. Objective regression in non-small cell lung cancer patients treated in phase I trials of oral ZD 1839 (Iressa), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR) [abstract 233]. Lung Cancer 2000;29(Suppl 1):72.
25. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002;20:4292-302.
26. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-25.
27. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-50.
28. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
29. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
30. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-92.
31. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;61:7184-8.
32. Cappuzzo F, Gregorc V, Rossi E, Cancellieri A, Magrini E, Paties CT, et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 2003; 21:2658-63.
33. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumors. 3rd ed. Berlin (Germany): Springer; 1999.
34. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-6.
35. Meier R, Alessi DR, Cron P, Andjelkovic M, Hemmings BA. Mitogenic activation, phosphorylation, and nuclear transiocation of protein kinase Bbeta. J Biol Chem 1997;272:30491-7.
36. Therasse P. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
37. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1985;53:457-81.
38. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
39. Agresti A. Categorical data analysis. New York (NY): John Wiley & Sons; 1990.
40. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 2003;9:4340-6.
41. Shah NT, Miller VA, Kris MG, Patel J, Venkatraman E, Benporat L, et al. Bronchioloalveolar histology and smoking history predict response to gefitinib [abstract 2524]. Proc ASCO 2003;22:628.
42. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983;1:511-29.
43. Perez-Soler R, Dai Q, Ling YH, Zou Y, Lia M, Kroog G, et al. Molecular mechanisms of sensitivity and resistance to the HER1/EGFR tyrosine Kinase inhibitor erlotinib [abstract 0-247]. Lung Cancer 2003;41:s72.
44. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004;22:777-84.
45. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004;22:785-94.
46. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003;22:2812-22.
47. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003;9:2316-26.
48. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
49. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.